DIA: Woodcock, other top officials tout benefits of master protocols, want momentum to continue post-COVID

Regulatory News

Regulatory NewsJoanne S. Eglovitch

Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyResearch, Design and Development